Use of gene expression and pathway signatures to characterize the complexity of human melanoma

American Journal of Pathology

Volumn 178, Issue 6, 2011, Pages 2513-2522

  Freedman, Jennifer A ^a   Tyler, Douglas S ^a   Nevins, Joseph R ^a,b   Augustine, Christina K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53; PROTEIN P63; STAT3 PROTEIN;

ARTICLE; BENIGN TUMOR; GENE CLUSTER; GENE EXPRESSION SYSTEM; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS; MOLECULAR MECHANICS; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CLASSIFICATION;

EID: 79959461288     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.02.037     Document Type: Article

References (44)

1. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu CC, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274 (Pubitemid 44571966)
2. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B: The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113 (Pubitemid 350134889)
3. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR: Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A 2009, 106:16387-16392
4. Hudis CA: Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51 (Pubitemid 47026733)
5. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446: 758-764 (Pubitemid 46582031)
6. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M: Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898 (Pubitemid 350231325)
7. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan M, Cibulskis K, Sougnez C, Wilson RK: Somatic mutations effect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075
8. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008, 68:664-673 (Pubitemid 351206741)
9. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353: 2135-2147 (Pubitemid 41653105)
10. Bastian BC, Olshen AB, LeBoit PE, Pinkel D: Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003, 163:1765-1770 (Pubitemid 37310008)
11. Maldonado JL, Fridlyand J, Patel HN, Jain AN, Busam KJ, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC: Determinants of BRAF mutations in primary melanomas. J Natl Canc Inst 2003, 95:1878-1890
12. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, Sirovich R, Risio M, Chiorino G: Altered molecular pathways in melanocytic lesions. Int J Cancer 2010, 126:1869-1881
13. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M: The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005, 102:6092-6097 (Pubitemid 40594260)
14. Smith AP, Hoek K, Becker D: Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 2005, 4:1018-1029 (Pubitemid 41598600)
15. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M: Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007, 13:806-815 (Pubitemid 46340353)
16. Lewis TB, Robison JE, Bastien R, Milash B, Coucher K, Samlowski WE, Leachman SA, Dirk Noyes R, Wittwer CT, Perreard L, Bernard PS: Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 2005, 104: 1678-1686 (Pubitemid 41437431)
17. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, GiDietrich K, Beaudry C, Berens M, Alberts D, Sondak V, Hayward N, Trent J: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540 (Pubitemid 30625740)
18. Bild A, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi M-B, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439: 353-357 (Pubitemid 43128862)
19. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR: A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 2010, 107:6994-6999
20. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics 2010, 3:26
21. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: Melanoma of the Skin. New York, Springer, 2002, pp 209-217
22. Carvalho C, Chang J, Lucas J, Nevins JR, Wang Q, West M: Highdimensional sparse factor modelling: applications in gene expression genomics. J Am Stat Assoc 2008, 103:1438-1456
23. Lucas J, Carvalho C, West M: A bayesian analysis strategy for crossstudy translation of gene expression biomarkers. Stat Appl Genet Mol Biol 2009, 88:Article 11
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550 (Pubitemid 41528093)
25. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamyo P, Spiegelman BM, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpharesponsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273 (Pubitemid 36792858)
26. Chang JT, Nevins JR: GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006, 22:2926-2933 (Pubitemid 44811565)
27. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A: Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 2007, 11:1052-1068 (Pubitemid 350041638)
28. Hocker TL, Singh MK, Tsao H: Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008, 128:2575-2595
29. Adhikary S, Eilers M: Transcription regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005, 6:635-645 (Pubitemid 41081267)
30. Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999, 19:1-11 (Pubitemid 29018404)
31. Box NF, Terzian T: The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008, 21:525-533
32. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER: Frequent nuclear/ cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999, 154:325-329 (Pubitemid 29094082)
33. Kraehn GM, Schartl M, Peter RU: Human malignant melanoma: a genetic disease? Cancer 1995, 75:1228-1237
34. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992, 327:516-523
35. Lee JK, Coutant C, Kim Y-C, Qi Y, Theodorescu D, Symmans WF, Baggerly KA, Rouzier R, Pusztai L: Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010, 16:711-718
36. Buettner R, Mesa T, Vultur A, Lee F, Jove R: Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008, 6:1766-1774
37. Fraser CK, Lousberg EL, Guerin LR, Hunges TP, Brown MP, Diener KR, Hayball JD: Dasatinib alters the metastatic phenotype of B16- OVA melanoma in vivo. Cancer Biol Ther 2010, 10:715-727
38. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560 (Pubitemid 38658421)
39. Augustine CK, Jung SH, Sohn I, Yoo JS, Yoshimoto Y, Olson JA Jr, Friedman HS, Ali-Osman F, Tyler DS: Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther 2010, 9:779-790
40. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599
41. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819
42. Tarhini AA, Kirkwood JM: Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci 2009, 1182:47-57
43. Jonsson G, Busch CMC, Knappskog S, Geisler J, Miletic H, Ringner M, Lillehaug JR, Borg A, Lonning PE: Gene expression profilingbased identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010, 16:3356-3367
44. Jilaveanu LB, Aziz SA, Kluger HM: Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 2009, 27: 614-625